Diane Harper | Cancer Prevention | Best Research Article Award

Published on by Network Science

Dr. Diane Harper | Cancer Prevention | Best Research Article Award

University of Michigan | United States

Author Profiles

Scopus

Google Scholar

Dr. Diane Harper: A Distinguished Career in Medicine and Public Health

Early Academic Pursuits

Dr. Diane Harper’s academic foundation reflects an extraordinary blend of science, engineering, and medicine. She earned dual degrees from the Massachusetts Institute of Technology (SB in Chemical Engineering, 1980; SM in Polymerics, 1982) before pursuing her MD at the University of Kansas Medical School (1986). Further strengthening her research expertise, she obtained a Master of Public Health in Biostatistics and Epidemiology (1995). These early academic pursuits equipped her with a unique interdisciplinary perspective, combining rigorous scientific training with clinical and public health applications.

Professional Endeavors

Dr. Harper’s professional career spans clinical practice, academic leadership, and health policy advisory roles. She trained extensively in gynecology, family medicine, oncology, and medical decision-making at renowned institutions such as Harvard, Stanford, UCSF, McMaster University, and the NIH. Her leadership development programs at the University of Michigan, Bellarmine School of Business, and ELAM further advanced her ability to guide teams in academic medicine. Professionally, she has held faculty, research, and advisory positions that allowed her to impact both patient care and the broader medical community.

Contributions and Research Focus

Dr. Harper is internationally recognized for her groundbreaking research on human papillomavirus (HPV) vaccination, cervical cancer prevention, and screening strategies. She has been instrumental in clinical trials and policy discussions on HPV vaccines, often serving as a critical voice in balancing scientific evidence with public health implementation. Her contributions also extend to training physicians in evidence-based medicine, advancing women’s health initiatives, and exploring psychosocial impacts of cancer prevention strategies.

Impact and Influence

Her impact resonates globally-through over 348 invited lectures and more than 137 international talks, she has influenced health policies, vaccination strategies, and screening practices worldwide. From Europe to Africa, Asia to the Americas, her expertise has shaped guidelines and public understanding of HPV prevention. She has also been recognized for integrating patient-centered perspectives into discussions of vaccine efficacy, safety, and accessibility.

Academic Cites and Recognition

Dr. Harper’s research is widely cited in scientific literature, reflecting her role as a thought leader in cancer prevention. She has authored high-impact publications and has been recognized with numerous national and international awards, including the Curtis G. Hames Research Award, STFM Excellence in Education Award, EuroGin Distinguished Service Award for Cancer Prevention, and the Prix Monte-Carlo Femme de l’Année. Her service on boards, advisory groups, and task forces—including the U.S. Preventive Services Task Force-further highlights her scholarly and policy influence.

Legacy and Future Contributions

Dr. Harper’s legacy lies in her dual commitment to advancing science and protecting public health. Her pioneering work on HPV vaccines has saved countless lives and continues to inform cancer prevention strategies worldwide. Looking forward, her contributions are expected to influence the next generation of researchers and policymakers, particularly in refining strategies for cancer screening, ensuring equitable access to vaccines, and fostering evidence-based decision-making in medicine.

Conclusion

Dr. Diane Harper’s career embodies the ideal integration of scientific innovation, clinical expertise, and public health leadership. Her work has not only advanced academic knowledge but has also transformed preventive health strategies on a global scale. As her legacy continues to inspire, her future contributions promise to shape the evolving landscape of cancer prevention and women’s health, leaving an indelible mark on medicine and society.

Notable Publications

"p16/ki‐67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions" 

  • Author: DM Harper, T Paczos, R Ridder, WK Huh
  • Journal: International Journal of Cancer
  • Year: 2025

"Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review" 

  • Author: DM Harper, JA Navarro-Alonso, FX Bosch, J Paavonen, M Stanley
  • Journal: Human Vaccines & Immunotherapeutics
  • Year: 2025

"Comparison of Human Papillomavirus genotyping by research vs. clinical assay for two self-collection devices" 

  • Author: DM Harper, AP Young, MC O’Dwyer, M Olorunfemi, A Laurie, A Sen
  • Journal: Cancer Epidemiology
  • Year: 2025

"A Novel Multi-Strain Vaginal Synbiotic Is Effective in Inhibiting Microbes Associated With Vaginal Dysbiosis, Inflammation, and Mucus Barrier Degradation" 

  • Author: Tawfiq Taleb Tawfiq; Hala Tawaha; Asem Tahtamouni; Nashat Ali Almasria
  • Journal: J Ravel, S Simmons, D Harper
  • Year: 2024

"The Canadian/United States primary care research partnership" 

  • Author: DM Harper, VR Ramsden
  • Journal: Annals of Family Medicin
  • Year: 2022

 

Cora Sternberg | Meta analysis | Outstanding Scientist Award

Published on by Network Science

Dr. Cora Sternberg | Meta analysis | Outstanding Scientist Award

Weill Cornell Medicine | United States

Author Profiles

Scopus

Orcid ID

Google Scholar

Early Academic Pursuits

Dr. Cora Sternberg’s academic journey reflects her commitment to excellence from the outset. She completed her medical training with distinction and pursued advanced fellowships, including a Research Fellowship in Immunology at the National Institutes of Health (1976–1977). Her early academic roles as Teaching Assistant at Stanford and Mount Sinai, followed by Clinical Instructor at Cornell University, laid the foundation for her lifelong dedication to education and clinical research. Her Phi Beta Kappa distinction from the University of Pennsylvania marked the start of a career dedicated to innovation and leadership in oncology.

Professional Endeavors

Over four decades, Dr. Sternberg has held prestigious academic and clinical leadership roles. She was Chief of Medical Oncology at San Camillo-Forlanini Hospital in Rome and served as Professor at La Sapienza University, shaping Italy’s oncology community. Since 2018, she has been Professor of Medicine and Clinical Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine and New York-Presbyterian. She has also served as a global faculty member at Temple University, Tufts University, and European institutions.

Contributions and Research Focus

Dr. Sternberg has pioneered groundbreaking research in prostate cancer, bladder cancer, and renal cell carcinoma. She was instrumental in developing practice-changing therapies such as abiraterone, enzalutamide, and darolutamide, significantly improving survival outcomes for prostate cancer patients. Her work in urothelial cancer led to the establishment of M-VAC chemotherapy and global adoption of immunotherapy protocols. She also contributed to the development of pazopanib and other targeted therapies in renal cell carcinoma. Recently, she has expanded her research focus to artificial intelligence in oncology, spearheading initiatives to integrate AI into therapeutic decision-making.

Impact and Influence

With over 546 publications, six textbooks, and more than 45,200 citations, Dr. Sternberg ranks among the World’s Top 2% Scientists (Stanford University) and the top 5% in the Doximity community for citations. She has delivered more than 835 lectures worldwide, influencing clinical practice, policy, and guidelines in oncology. Her leadership roles in international organizations such as ASCO, ESMO, ECCO, and EORTC demonstrate her far-reaching influence.

Academic Citations

Dr. Sternberg’s research impact is widely recognized. Her publications in high-impact journals such as New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology have shaped global treatment standards. Her works are consistently cited in clinical guidelines, trial protocols, and oncology education, affirming her stature as a thought leader in medical oncology.

Legacy and Future Contributions

Dr. Sternberg’s legacy lies not only in transformative research but also in mentorship. She has nurtured generations of oncologists, fostering innovation and translational research. Currently, she co-leads the Career Development Program in the Bladder SPORE initiative, ensuring the pipeline of future oncology leaders. Her pioneering role in AI in oncology positions her to continue shaping the future of precision medicine, bridging clinical care with technological innovation.

Conclusion

Dr. Cora Sternberg exemplifies the qualities of an Outstanding Scientist—visionary leadership, transformative research, global influence, and unwavering dedication to advancing oncology. Her lifelong contributions to clinical practice, groundbreaking research, academic mentorship, and adoption of emerging technologies ensure her lasting impact on the medical community and future generations of scientists.

Notable Publications

"Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100" 

  • Author: homas Powles; Srikala S. Sridhar; Joaquim Bellmunt; Cora N. Sternberg; Petros Grivas; Ewan Hunter; Matthew Salter; Ryan Powell; Ann Dring; Jayne Green et al.
  • Journal: Cancers
  • Year: 2025

"The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making" 

  • Author: Olivier Elemento; Sean Khozin; Cora N. Sternberg
  • Journal: NEJM AI
  • Year: 2025

"Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100" 

  • Author: Thomas Powles; Srikala S. Sridhar; Joaquim Bellmunt; Cora N. Sternberg; Petros Grivas; Ewan Hunter; Matthew Salter; Ryan Powell; Ann Dring; Jayne Green et al.
  • Journal: Preprint
  • Year: 2025

"Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591" 

  • Author: Scott T. Tagawa; Charlene Thomas; A. Oliver Sartor; Michael Sun; Judith Stangl-Kremser; Mahelia Bissassar; Shankar Vallabhajosula; Sandra Huicochea Castellanos; Jones T. Nauseef; Cora N. Sternberg et al.
  • Journal: Journal of Clinical Oncology
  • Year: 2024

"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial" 

  • Author: Maha Hussain; Bertrand Tombal; Fred Saad; Karim Fizazi; Cora N. Sternberg; E. David Crawford; Neal Shore; Evgeny Kopyltsov; Arash Rezazadeh Kalebasty; Martin Bögemann et al.
  • Journal: Journal of Clinical Oncology
  • Year: 2023

 

 

Zhengyang Guo | Metabolism Networks | Best Researcher Award

Published on by Network Science

Dr. Zhengyang Guo | Metabolism Networks | Best Researcher Award

Peking University Third Hospital | China

Author Profile 

Scopus

Early Academic Pursuits

Zhengyang Guo’s academic journey began with a strong foundation in the life sciences. He earned his Bachelor’s degree from the School of Basic Medical Sciences at Peking University, which provided him with comprehensive knowledge in biomedical sciences. His pursuit of higher education continued at the Department of Microbiology, Peking University, where he obtained his M.D. degree. This academic background not only reflects his commitment to advancing medical research but also highlights the interdisciplinary foundation that shaped his later contributions in oncology and immunology.

Professional Endeavors

Currently serving as an Assistant Professor at Peking University Third Hospital, Guo has dedicated his professional career to the study of tumor biology and clinical translational research. Alongside his teaching responsibilities, he actively contributes to developing cutting-edge techniques through his involvement in the immunology platform and guiding graduate students in experimental teaching. His professional endeavors balance research, teaching, and technological development, underlining his role as both a researcher and mentor.

Contributions and Research Focus

Dr. Guo’s research primarily centers on tumor epigenetics, tumor metabolism, and the tumor microenvironment. His innovative work investigates molecular mechanisms that influence cancer progression and therapeutic outcomes. Specifically, he has focused on targeting the enzyme SCD1 in combination with EZH2 inhibitors to enhance the efficacy of melanoma treatment and immunotherapy. His projects, supported by prestigious funding bodies such as the National Natural Science Foundation of China and Peking University Medicine Fund, reflect both the clinical relevance and scientific novelty of his work.

Impact and Influence

As an active contributor to the global scientific community, Guo holds membership in the Biophysical Society of China and the Chinese Society of Biochemistry and Molecular Biology. His expertise is recognized internationally, as he serves as a peer reviewer for high-impact journals including Experimental Hematology & Oncology, Cell Communication and Signaling, Apoptosis, and Lipids in Health and Disease. These engagements highlight his influence in shaping scientific dialogue and advancing standards in cancer research.

Academic Cites and Intellectual Property

Guo’s research impact extends beyond publications into intellectual property and patents. He is a co-inventor on multiple patents related to antitumor drug compositions involving EZH2 and SCD1 inhibitors, as well as novel approaches to treating liver cancer using diacylglycerol kinase γ. These patents underscore the translational potential of his work, bridging basic molecular research with therapeutic innovation. His contributions are already shaping new pathways in drug discovery and cancer therapy.

Legacy and Future Contributions

With a strong foundation of academic excellence, innovative research, and translational breakthroughs, Guo is poised to make long-lasting contributions to the field of oncology. His ongoing efforts in epigenetic regulation, tumor metabolism, and immunotherapy strategies hold promise for redefining cancer treatment paradigms. By mentoring future scholars and fostering collaborations across disciplines, he is actively building a legacy that will continue to influence both academia and clinical practice.

Conclusion

In summary, Dr. Zhengyang Guo exemplifies the qualities of a modern medical researcher-a scholar who bridges fundamental biology with clinical application. His journey from early academic pursuits to groundbreaking research in tumor biology reflects dedication, innovation, and leadership. With multiple funded projects, patents, and international recognition, his work significantly impacts the scientific community and promises future advancements in cancer treatment. His career trajectory positions him as a leading figure in biomedical research, with the potential to transform cancer therapy at both national and global levels.

Notable Publications

"3G Internet Diffusion and Secondary Education Attainment: Evidence of Opportunity Cost in Vietnam" 

  • Author: Trang Thi Pham; Bernardo Caldarola
  • Journal: Review of Development Economics
  • Year: 2025